Neuroendocrine Cancer is the fastest growing segment fueling the growth of Pituitary Cancer Market

The pituitary cancer market comprises of medical treatment options for patients diagnosed with pituitary cancer. Pituitary cancers are rare tumors that start in the pituitary gland which is a pea-sized gland located at the base of the brain.

 The global Pituitary Cancer Market is estimated to be valued at US$ 380.7 Mn in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
  

Market key trends:

One of the key trends fueling the growth of the pituitary cancer market is rising preference of targeted drug therapy over conventional chemotherapy. Targeted drug therapies mainly include somatostatin analogs and dopamine agonists which directly act on cancer cells and have less side effects compared to chemotherapy. These targeted drugs are effective in controlling symptoms and slowing tumor growth in patients with hormone secreting pituitary adenomas and carcinomas. The targeted approach offers better quality of life for patients and is thus increasingly adopted.

Segment Analysis
The global pituitary cancer market is segmented on the basis of type, treatment, and end user. Based on type, the market is categorized into pituitary adenomas (prolactinoma, acromegaly, Cushing's disease, and others) and craniopharyngioma. Of these, pituitary adenomas dominate the segment as they accounts for majority of pituitary cancers cases. Prolactinoma is the most common type of pituitary adenoma.

Based on treatment, the market is divided into surgery, radiation therapy, medication, and others. Surgery remains the primary treatment option for managing pituitary cancers. However, radiation therapy segment is expected to grow at a higher CAGR during the forecast period due to the increasing preference for radiation therapy post-surgery.

On the basis of end user, the market covers hospitals & clinics and academic research institutes. Hospitals & clinics holds the largest share in the market due to growing number of pituitary cancer diagnosis and treatment procedures undertaken at hospitals.

Key Takeaways
The global pituitary cancer market is expected to witness high growth, exhibiting CAGR of 9.6% over the forecast period, due to increasing incidence of pituitary tumors globally.

North America dominates the global market and is expected to continue its dominance over the forecast period. This is attributed to increasing healthcare expenditure, growing awareness about pituitary cancer diagnosis and treatment, and presence of key players in the region. Europe is projected to be the second largest and fastest growing market for pituitary cancer during the forecast period.

Key players operating in the pituitary cancer market are Novartis International AG, Pfizer Inc., Ipsen Biopharmaceuticals, Inc., Endocyte, RECORDATI GROUP, Camurus AB, Endeavor Biomedicines, Inc., and Debiopharm International SA. Major players are focusing on expanding their product portfolios by developing new medications for effective management of pituitary cancer.

Comments

Post a Comment

Popular posts from this blog

The global Rabies Antiserum Market Growth Accelerated by increasing prevalence of animal rabies infections

Image
 Rabies Antiserum is a solution derived from the blood of animals that have been immunized against rabies. It is administered to individuals who have high risk of developing rabies, such as those who have been bitten or scratched by an animal suspected of being infected. The global Rabies Antiserum Market is estimated to be valued at US$ 1.24 Bn in 2023 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Rabies Antiserum neutralises the rabies virus to prevent the onset of disease in individuals exposed to the virus. The increasing prevalence of animal rabies infections has prompted greater prevention efforts through pre- and post-exposure prophylaxis using rabies biologics such as Rabies Antiserum. Market key trends: The growing prevalence of rabies infections among animals, particularly dogs, worldwide has been a major factor driving the increasing demand for rabies antiserum. A
Read more

Fibrinolytic Therapy is Anticipated to Witness Moderate Growth Owing to Rising Prevalence of Cardiovascular Diseases

Image
The global fibrinolytic therapy market is estimated to be valued at US$ 34.96 Bn in 2024 and is expected to exhibit a CAGR of 3.7% over the forecast period of 2023 to 2030. Fibrinolytic therapy, also called thrombolysis, involves the use of clot-busting drugs to dissolve blood clots and restore blood flow. Rising prevalence of cardiovascular diseases such as heart attacks and strokes has increased the demand for fibrinolytic drugs worldwide. Fibrinolytic therapy improves patient outcomes and recovery rates by dissolving the clots blocking arteries and restoring blood flow to tissues and organs. Key players operating in the fibrinolytic therapy market are Genentech, Inc. (Roche), Bayer AG, Boehringer Ingelheim International GmbH, Pfizer Inc., Bristol Myers Squibb Company, Novartis AG, AstraZeneca PLC, Johnson & Johnson, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Mallinckrodt Pharmaceuticals, Mitsub
Read more